Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Real-world data comparing the efficacy and safety of axi-cel & tisa-cel in DLCBL

Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, briefly comments on real-world data on the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in diffuse large B-cell lymphoma (DLBCL). Although further data is needed to confirm this, evidence suggests that tisa-cel is more tolerable than axi-cel, and axi-cel has been reported to be more effective than tisa-cel in some studies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Allogene, Amgen, BMS, Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar and Novartis: Consultancy.